A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)

Trial Profile

A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs BL 8040 (Primary) ; Antithymocyte globulin; Ciclosporin; Methylprednisolone; Prednisone
  • Indications Aplastic anaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors BioLineRx
  • Most Recent Events

    • 17 Jun 2018 Interim results (n=8) presented at the 23rd Congress of the European Haematology Association
    • 16 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2018.
    • 16 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top